CLLS
Cellectis S.A.
NASDAQ · Healthcare · Biotechnology · FR
$3.24
−2.41%Institutional positioning
13F filings over the trailing two quarters
New 5Increased 3Reduced 14Sold out 32
| Filer | Action | Shares | Filed |
|---|---|---|---|
| B GROUP, INC. | Unchanged | 3,281,501 | May 15, 2026 |
| UBS ASSET MANAGEMENT AMERICAS INC | Unchanged | 3,178,620 | May 13, 2026 |
| LONG FOCUS CAPITAL MANAGEMENT, LLC | Reduced | 2,744,098 | May 15, 2026 |
| BLACKROCK, INC. | Reduced | 341,523 | May 13, 2026 |
| MACQUARIE MANAGEMENT HOLDINGS, INC. | Unchanged | 226,875 | May 15, 2026 |
| MORGAN STANLEY | Reduced | 86,776 | May 15, 2026 |
| LPL FINANCIAL LLC | Reduced | 84,345 | May 6, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Increased | 65,942 | May 15, 2026 |
| CITADEL ADVISORS LLC | Reduced | 44,315 | May 15, 2026 |
| MARSHALL WACE, LLP | Reduced | 41,112 | May 15, 2026 |
| BNP PARIBAS ARBITRAGE, SNC | Reduced | 41,000 | May 12, 2026 |
| UBS GROUP AG | Reduced | 29,774 | May 5, 2026 |
| DELANEY DENNIS R | Unchanged | 24,000 | May 14, 2026 |
| XTX TOPCO LTD | New Position | 16,269 | May 15, 2026 |
| RHUMBLINE ADVISERS | Increased | 15,085 | May 12, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings